Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 21
Filter
Add more filters










Publication year range
1.
J Pharmacol Exp Ther ; 277(1): 253-64, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8613928

ABSTRACT

Befloxatone, a novel oxazolidinone derivative, inhibited selectively and competitively monoamine oxidase (MAO)-A in human and rat brain, heart, liver and duodenum homogenates with Ki values ranging from 1.9 to 3.6 nM for MAO-A and from 270 to 900 nM for MAO-B. In vitro, befloxatone was more potent at inhibiting MAO-A activity than reference compounds (befloxatone > harmaline > brofaromine > BW 137OU87 > RS 8359 > toloxatone > moclobemide). The inhibition of MAO-A by befloxatone was time-dependent and fully reversible after dilution. After p.o. administration, befloxatone induced a dose-dependent and selective inhibition of rat brain and duodenum MAO-A activities ex vivo with ED50 values of 0.06 and 0.025 mg/kg, respectively. Befloxatone (0.5 mg/kg p.o.) decreased MAO-B activity by only 20% in both tissues. In the brain, liver and duodenum, the inhibition of MAO-A activity by befloxatone was short lasting. Twenty-four hours after administration of befloxatone (0.75 mg/kg p.o.), a full recovery of MAO-A activity was observed in the brain, but the enzyme activity was still decreased by 38 and 56% in the duodenum and liver, respectively. In the rat brain, befloxatone (0.75 mg/kg p.o.) increased levels of norepinephrine, dopamine and 5-hydroxytryptamine and decreased levels of their respective deaminated metabolites. These variations were dose-dependent and reversed 24 hr after administration. In addition, befloxatone (0.75 mg/kg p.o.) decreased free 3,4-dihydroxyphenylethylene glycol levels in the brain and plasma. Befloxatone (10 microM) did not modify the activities of diamine or benzylamine oxidase and did not interact with monoamine uptake mechanisms or with a variety of neurotransmitter or drug receptor sites. In conclusion, the neurochemical profile of befloxatone demonstrates that this compound is a selective, competitive, potent and reversible MAO-A inhibitor.


Subject(s)
Monoamine Oxidase Inhibitors/pharmacology , Oxazoles/pharmacology , Animals , Biogenic Monoamines/analysis , Biogenic Monoamines/metabolism , Brain/enzymology , Duodenum/enzymology , Humans , Liver/enzymology , Male , Methoxyhydroxyphenylglycol/analogs & derivatives , Methoxyhydroxyphenylglycol/analysis , Rats , Rats, Sprague-Dawley
2.
J Pharmacol Exp Ther ; 277(1): 265-77, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8613929

ABSTRACT

The pharmacological profile of befloxatone, a reversible, selective and competitive inhibitor of monoamine oxidase-A has been investigated in rodents. In mice, befloxatone was more active at potentiating generalized tremors induced by L-5-hydroxytryptophan (ED50, 0.21 mg/kg p.o.) than phenylethylamine-induced stereotypies (ED50, 58 mg/kg p.o.), indicating a very high in vivo selectivity for inhibition of the A form of monoamine oxidase. Befloxatone showed potent activity in behavioral models in rodents predictive of antidepressant activity (forced swimming test, learned helplessness and reserpine reversal) with minimal effective doses of 0.1 to 0.2 mg/kg p.o. In these tests, befloxatone was much more potent (10- to 500-fold) than reference antidepressant compounds (reversible and irreversible monoamine oxidase inhibitors and monoamine reuptake inhibitors). In rats, befloxatone increased rapid eye movement sleep latency and decreased rapid eye movement sleep duration, without rebound effects. Potential anxiolytic activity was observed in the elevated-plus maze test in rats (minimal effective dose, 1-2 mg/kg p.o.). Befloxatone had no effect on motor performance, did not induce sedative or stimulant activity up to doses of 200 mg/kg p.o. and was devoid of anticholinergic activity in mice. Interaction studies with p.o. dietary tyramine (12 mg/kg), carried out in freely moving rats, demonstrated that, in contrast to irreversible monoamine oxidase inhibitors, befloxatone did not potentiate the pressor effect of this amine in the range of doses which showed pharmacological activity in antidepressant behavioral models. Furthermore, of the compounds tested (moclobemide, brofaromine, nialamide and phenelzine), comparison of doses active in antidepressant models and doses potentiating the pressor effects of tyramine demonstrated that befloxatone had the best therapeutic index. The results suggest that befloxatone will show clinical antidepressant activity at low doses and will be devoid of the side effects associated with irreversible monoamine oxidase inhibitors.


Subject(s)
Monoamine Oxidase Inhibitors/pharmacology , Oxazoles/pharmacology , Animals , Anti-Anxiety Agents/pharmacology , Antidepressive Agents/pharmacology , Cholinergic Antagonists/pharmacology , Male , Mice , Motor Activity/drug effects , Rats , Rats, Sprague-Dawley , Sleep, REM/drug effects , Swimming , Tyramine/pharmacology
3.
J Nucl Biol Med (1991) ; 38(4 Suppl 1): 63-8, 1994 Dec.
Article in English | MEDLINE | ID: mdl-7632770

ABSTRACT

3-Bromobenzyloxy phenyloxy hydroxymethyl propanol was labelled with iodine-125. Labeling yield was approximately 92%. Using HPLC and an RP18 column, Iodo*MD (MW = 412) was obtained at no-carrier-added conditions (specific activity 125 Ci/mmole). Biochemical experiments were carried out in vitro and showed a Ki for MAO-B of 5.4 nM and of 5000 for MAO-A (RA/B = 926). Using ex vivo kinetic inhibition in rat (dose: 5 mg/kg p.o.), the results demonstrated a strong similarity of action with BromoMD and IodoMD, with an inhibition percentage that decreased with time (91% at 1 hour, 48% at 8 hours, 2% at 24 hours). The rat brain Iodo*MD concentration was maximal after the first pass and inhibition decreased slowly with time (T1/2 = 1.8 hours). Uptake and wash-out of Iodo*MD was studied on two-day-old rat astrocytes in culture. Half-times of uptake and efflux were respectively 2.5 minutes and 7.5 minutes. The use of metabolic inhibitors (KCN and Digoxin) suggested the absence of any active transport. Binding studies with various concentration of cold MD 360194 showed that at 10(-8) M the uptake decreased significantly. Rats were dissected at different times post i.v. injection (0-2 hours), and the principal organs and brain were obtained (the brain was separated into 7 pieces). Radioactivity was concentrated mainly in the liver (24.6 +/- 4%), fat (12.4 +/- 3.4%) and muscles (18.4 +/- 3%). In the brain the concentration was approximately 1.2 +/- 0.3% within 30 minutes post i.v. injection and 0.84 +/- 0.15% thereafter. The hypothalamus and striatum were two-fold more active than the cortex.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Astrocytes/diagnostic imaging , Brain/diagnostic imaging , Iodine Radioisotopes , Monoamine Oxidase Inhibitors , Phenyl Ethers , Propanols , Propylene Glycols , 1-Propanol/pharmacokinetics , Animals , Cells, Cultured , In Vitro Techniques , Isotope Labeling , Male , Phenyl Ethers/pharmacokinetics , Rats , Rats, Wistar , Tissue Distribution , Tomography, Emission-Computed, Single-Photon
4.
J Neural Transm Suppl ; 41: 313-9, 1994.
Article in English | MEDLINE | ID: mdl-7931244

ABSTRACT

Experimental and theoretical physico-chemical methods were used to investigate the interaction between aryl-oxazolidinones and monoamine oxidase (MAO). Several arguments suggest that these compounds interact with the flavin adenine dinucleotide (FAD) cofactor of MAO. The calculation using ab initio molecular orbital methods of the electronic properties of flavin and befloxatone, a reversible inhibitor of MAO A, led to a description of the interaction between aryl-oxazolidinones and the cofactor of the enzyme. Structure activity relationship results revealed additional sites of interaction with the protein core of MAO A. As a result of this work, a model is proposed for the reversible inhibition of MAO by oxazolidinones via long distance, reversible interactions with the FAD cofactor of the enzyme.


Subject(s)
Models, Chemical , Monoamine Oxidase Inhibitors/chemistry , Monoamine Oxidase Inhibitors/pharmacology , Chemical Phenomena , Chemistry, Physical , Oxazoles/chemistry , Oxazoles/pharmacology , Structure-Activity Relationship , X-Ray Diffraction
5.
J Neural Transm Suppl ; 41: 339-47, 1994.
Article in English | MEDLINE | ID: mdl-7931248

ABSTRACT

In vitro and ex-vivo studies show that befloxatone, a new oxazolidinone derivative, is a potent, reversible, competitive and specific MAO-A inhibitor (KiA from 1.9 to 3.6 nM and KiB/KiA ratio between 100 and 400, in the Rat and in Man, depending on the tissue). Befloxatone possesses a marked activity in antidepressant-sensitive behavioral models in rats (from 0.03 to 0.15 mg/kg po) and mice (from 0.21 to 0.29 mg/kg po). At these doses, befloxatone does not induce a significant potentiation of oral tyramine. Befloxatone is devoid of sedative, anticholinergic and cardiovascular effects. Befloxatone is rapidly and extensively distributed in rat brain, the pharmacokinetics are linear in the rat and in man in a large range of doses. Befloxatone is well tolerated in healthy volunteers and is developed as an antidepressant.


Subject(s)
Monoamine Oxidase Inhibitors/pharmacology , Oxazoles/pharmacology , Animals , Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Brain/metabolism , Drug Interactions , Humans , In Vitro Techniques , Male , Mice , Mice, Inbred Strains , Monoamine Oxidase/metabolism , Oxazoles/chemistry , Oxazoles/pharmacokinetics , Rats , Rats, Sprague-Dawley , Tyramine/pharmacology
6.
J Neural Transm Suppl ; 41: 349-55, 1994.
Article in English | MEDLINE | ID: mdl-7931249

ABSTRACT

Single administration of befloxatone (0.75 mg/kg, i.p.) in the rat increased extracellular levels of DA (+300%) in striatum. In frontal cortex, befloxatone (0.75 mg/kg, i.p.) and nialamide (100 mg/kg, i.p.) increased NA by +100% but did not modify 5HT, whereas pargyline (100 mg/kg i.p.) increased extracellular NA and 5HT by 400 and 600%, respectively. At these doses, befloxatone inhibited totally and selectively MAO-A, pargyline inhibited totally MAO-A and MAO-B. Increases of tissue and extracellular concentrations of NA and 5HT were highest after Pargyline suggesting that both monoamines may be metabolized by MAO-A and MAO-B. Befloxatone and nialamide potentiated the effects of idazoxan (20 mg/kg, i.p.) on extracellular NA in frontal cortex, which increased from 350% to 2,000 and 1,500% respectively. These results suggest that alpha 2-adrenoceptors play a major role in the regulation of extracellular NA in frontal cortex.


Subject(s)
Biogenic Monoamines/metabolism , Cerebral Cortex/metabolism , Corpus Striatum/metabolism , Monoamine Oxidase Inhibitors/pharmacology , Monoamine Oxidase/metabolism , Oxazoles/pharmacology , Animals , Dopamine/metabolism , Male , Nialamide/pharmacology , Norepinephrine/metabolism , Pargyline/pharmacology , Rats , Rats, Sprague-Dawley , Serotonin/metabolism
7.
Fundam Clin Pharmacol ; 3(1): 67-78, 1989.
Article in English | MEDLINE | ID: mdl-2653992

ABSTRACT

Hemodynamic effects of LND-623, a new aminosteroid lacking the C17 lactone ring and the C14 hydroxyl group common to the natural glycosides, were studied in the pentobarbital-anesthetized dog and compared to those of its 20 alpha-isomer LND-369 and of digoxin and digoxigenin-rhamnoside (DRh). Twenty-four mongrel dogs were divided into 4 groups. Group I received either LND-623 or saline on study day 1 and the other drug or saline 1 wk later. Saline was replaced by digoxin in group II, digoxigenin-rhamnoside in group III, and LND-369 in group IV. All drugs except LND-369 were infused as 3.10(-9) mol.kg-1.min-1 over 20 minutes. LND-369 was infused at twice the dose. LND-623 increased left ventricular dP/dt for at least 3 h with a peak at end-infusion or 15 min later, accompanied by a transient vasopressor effect. LND-369 induced, at twice the dose, an inotropic effect of comparable magnitude but of shorter duration. Inversely, it provoked a more marked and prolonged vasopressor effect than its 20 beta-isomer, LND-623. Maximal digoxin inotropic effect occurred later but was of comparable magnitude to that induced by LND-623. Its vasopressor effects reached a plateau rapidly and remained sustained until min 200. Digoxigenin-rhamnoside inotropic but not vasopressor effects are weaker than those of LND-623. It is concluded that LND-623, although lacking the most common structural features of the natural cardiac glycosides, provoked rapid and sustained inotropic activities with transient vasopressor effects. These time-course effects differ from digoxin, and these differences are unrelated to their sugar-moiety characteristics. LND-623 inotropic effect is twice as potent as its 20 alpha-isomer.


Subject(s)
Digoxigenin/pharmacology , Digoxin/analogs & derivatives , Digoxin/pharmacology , Glycosides/pharmacology , Hemodynamics/drug effects , Mannosides/pharmacology , Pregnanes/pharmacology , Anesthesia , Animals , Blood Pressure/drug effects , Cardiac Output/drug effects , Dogs , Heart Rate/drug effects , Isomerism , Myocardial Contraction/drug effects , Renin/blood
8.
J Cardiovasc Pharmacol ; 12(4): 445-50, 1988 Oct.
Article in English | MEDLINE | ID: mdl-2465445

ABSTRACT

Pharmacokinetics and effects of oral hydroxy-3(S)-dihydroquinidine (3-OH-HQ) on heart rate (HR), blood pressure (BP), and ECG intervals were studied in 12 healthy volunteers. Three oral single doses of 3-OH-HQ (225, 450, and 900 mg) and placebo were randomly administered to each subject at one week intervals. Pharmacokinetics of 3-OH-HQ was linear in the range of administered doses, with rapid absorption (tmax 0.5-2.5 h) and distribution (t1/2 alpha 0.8-1.2 h) phases. Elimination half-lives did not significantly change with the three doses (15 +/- 4.3, 13.7 +/- 3.9, and 13 +/- 2.2 h). Unchanged 3-OH-HQ was partially eliminated by urine (mean renal clearance 0.24 +/- 0.02 L h-1 kg-1). 3-OH-HQ significantly increased HR after the three doses as compared to placebo. PR interval was not significantly modified but QRS duration significantly increased from 91 +/- 7 to 108 +/- 11 ms (p less than 0.001) 2 h after the 900 mg dose. QTc interval was significantly prolonged from 0.5 to 8 h after the highest dose (14.4 +/- 8.7% 1 h after dosing). Heart rate QRS, and QTc variations were significantly correlated to 3-OH-HQ plasma levels.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Quinidine/analogs & derivatives , Administration, Oral , Anti-Arrhythmia Agents/administration & dosage , Anti-Arrhythmia Agents/pharmacokinetics , Blood Pressure/drug effects , Electrocardiography , Heart Conduction System/drug effects , Heart Rate/drug effects , Humans , Intestinal Absorption , Male , Quinidine/administration & dosage , Quinidine/pharmacokinetics , Quinidine/pharmacology
10.
Eur Heart J ; 5 Suppl F: 309-14, 1984 Dec.
Article in English | MEDLINE | ID: mdl-6549446

ABSTRACT

It is usually postulated that the side chain attached to 17 beta position on the steroid nucleus of the cardioactive glycosides is a major determinant of their pharmacological activity. A new aminosteroid (LND 623) has been prepared. Despite the fact that the structural features quoted above are lacking, the product demonstrates a strong inotropic effect. LND 623 was active at the same range of concentrations as ouabain or digoxin. However, the maximum increase of the contractile force was significantly higher. The strength of the inotropic action is not modified in the presence of propranolol. The preliminary results suggest that the molecular requirements for the interaction of the drugs with the 'inotropic receptor' may be re-examined.


Subject(s)
Cardiotonic Agents/pharmacology , Glycosides/pharmacology , Heart/drug effects , Mannosides/pharmacology , Myocardial Contraction/drug effects , Pregnanes/pharmacology , Animals , Digoxin/pharmacology , Dogs , Dose-Response Relationship, Drug , Guinea Pigs , Male , Papillary Muscles/drug effects , Propranolol/pharmacology , Reserpine/pharmacology , Stimulation, Chemical , Structure-Activity Relationship
12.
Arch Mal Coeur Vaiss ; 72(9): 1006-13, 1979 Sep.
Article in French | MEDLINE | ID: mdl-116611

ABSTRACT

Arabogalactane sulphate of quinidine (AGSQ) is a slow release preparation of quinidine. The aim of this study was to compare the plasma levels of quinidine obtained by different preparations of AGSQ (AGSQ I, II and III) and to determine which was best suited to therapeutics. The "in vitro" study showed different amounts of quinidine liberated in 6 hours, 34% with AGSQ I, 58% with AGSQ II and 100% with AGSQ III. The plasma quinidine levels were studied after administration of a dose corresponding to 330 mg quinidine base, morning and evening for 7 consecutive days to 27 hospitalised patients; 7 received AGSQ I, 11 received AGSQ II 5, received AGSQ III and 4 quinidine sulphate. The delay in reaching a steady state was 24 hours for the quinidine sulphate 36 hours for AGSQ I, 48 hours for AGSQ II and 60 hours for AGSQ III. The average plasma level on the 7th day (Cee) was 2.74 +/- 0.71 microgram/ml, 2.62 +/- 0.74 microgram/ml and 3.29 +/- 0.72 microgram/ml respectively. The plasma quinidine levels were maintained between toxic and therapeutic levels (3,5 and 1,7 microgram/ml) only with AGSQ II by suppressing the peak observed 1 hour administration of quinidine sulphate. An excellent correlation (r = 0,984) was observed between the plasma quinidine 6 hours after ingestion and the Cee. A blood test during the steady state, 6 hours after ingestion of the drug, is useful in adjusting the dosage. These results suggest that AGSQ II is the preparation best suited for therapeutic usage although it does not give the best relative bioavailability of the drug.


Subject(s)
Quinidine/blood , Delayed-Action Preparations , Humans , Kinetics , Quinidine/administration & dosage , Quinidine/therapeutic use , Solubility
SELECTION OF CITATIONS
SEARCH DETAIL
...